The estimated Net Worth of Randal W. Scott is at least $13.5 Million dollars as of 3 June 2024. Randal Scott owns over 2,500 units of BridgeBio Pharma Inc stock worth over $111,960 and over the last 19 years he sold BBIO stock worth over $13,358,700. In addition, he makes $0 as Independent Director at BridgeBio Pharma Inc.
Randal has made over 29 trades of the BridgeBio Pharma Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of BBIO stock worth $75,800 on 3 June 2024.
The largest trade he's ever made was buying 66,666 units of BridgeBio Pharma Inc stock on 22 November 2016 worth over $399,996. On average, Randal trades about 6,589 units every 52 days since 2005. As of 3 June 2024 he still owns at least 4,000 units of BridgeBio Pharma Inc stock.
You can see the complete history of Randal Scott stock trades at the bottom of the page.
Dr. Randal W. Scott Ph.D. serves as Independent Director of the Company. He is the cofounder of Invitae Corporation, a genetic information company (NYSE: NVTA), where he served as the Chairman and CEO from 2012 to 2017 and the Executive Chairman from 2017 to 2019. Dr. Scott currently serves on the board of Invitae. Prior to that, Dr. Scott cofounded Genomic Health, Inc., a genetic research company (Nasdaq: GHDX), where he served as the Chairman and CEO from 2000 to 2009 and the Executive Chairman from 2009 to 2012. Dr. Scott holds a BS in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.
Randal Scott is 62, he's been the Independent Director of BridgeBio Pharma Inc since 2020. There are 7 older and 15 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
Randal's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo und Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: